ARTICLE | Politics & Policy
Former FDA, CMS heads commend importation, government negotiation to control drug prices
April 24, 2019 9:39 PM UTC
In an editorial published in JAMA, former FDA Commissioner Robert Califf and former CMS Acting Administrator Andrew Slavitt endorsed a wide range of policies to reduce drug costs, including targeted importation, cutting supply chain and marketing costs, government drug-price negotiation, and creation of a value-based reimbursement system.
Califf is a professor of medicine at Duke University and adviser and advisory board member at Verily Life Sciences. Slavitt is board chair at United States of Care, a non-profit healthcare advocacy group. ...